Comments

Response to Comment on: “Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia”

Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province,Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001
Precision Medicine Research Center, Beijing Lu Daopei Institute of Hematology, Beijing, China; Department of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang
Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province,Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001
Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province,Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, China; Shanxi University of Chinese Medicine, No. 121, University Street, Yuci District, Jinzhong City, Shanxi Province
Haematologica Early view May 21, 2026 https://doi.org/10.3324/haematol.2026.301167